Company Supernus Pharmaceuticals, Inc.

SUPN

US8684591089

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Supernus Pharmaceuticals, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
29.43 ^USD	-1.87%		-7.25%	+1.69%

Apr. 08	Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready	DJ
Apr. 08	Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket	MT

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinsonâs Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Number of employees: 652

USD in Million	2022	Weight	2023	Weight	Delta
Treatment of Central Nervous System Diseases 100.0 %	667	100.0 %	608	100.0 %	-8.95%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	667	100.0 %	608	100.0 %	-8.95%

Managers	Title	Age	Since
Jack Khattar FOU	Founder	62	05-03-29
Timothy Dec DFI	Director of Finance/CFO	66	21-08-22
Frank Mottola CTO	Chief Tech/Sci/R&D Officer	52	04-12-31
Jonathan Rubin CTO	Chief Tech/Sci/R&D Officer	62	20-01-31
Padmanabh P. Bhatt CTO	Chief Tech/Sci/R&D Officer	66	05-03-29
Kevin T. Anderson CMP	Compliance Officer	61	11-12-31
Taylor Raiford SAM	Sales & Marketing	-	14-12-31
Todd Horich SAM	Sales & Marketing	-	18-05-30
Bryan A. Roecklein PRN	Corporate Officer/Principal	-	15-06-30
Tami Martin LAW	General Counsel	68	07-12-31

Members of the board	Title	Age	Since
Georges Gemayel BRD	Director/Board Member	64	15-03-22
Charles Newhall CHM	Chairman	79	05-03-29
John Siebert BRD	Director/Board Member	84	10-12-31
Frederick Hudson BRD	Director/Board Member	78	10-11-15
Carrolee Barlow BRD	Director/Board Member	60	18-06-26
Jack Khattar FOU	Founder	62	05-03-29
Bethany Sensenig BRD	Director/Board Member	48	23-08-20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	54,734,956	51,934,710 ( 94.88 %)	0	94.88 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 17.98 %	9,841,300	17.98 %	336 M $
Vanguard Fiduciary Trust Co. 11.35 %	6,214,731	11.35 %	212 M $
Armistice Capital LLC 8.495 %	4,650,000	8.495 %	159 M $
Macquarie Investment Management Business Trust 5.002 %	2,737,716	5.002 %	93 M $
Dimensional Fund Advisors LP 4.488 %	2,456,369	4.488 %	84 M $
STATE STREET CORPORATION 3.768 %	2,062,326	3.768 %	70 M $
POLAR CAPITAL HOLDINGS PLC 3.543 %	1,939,365	3.543 %	66 M $
Jack Khattar 3.540 %	1,937,667	3.540 %	66 M $
Stephens Investment Management Group LLC 3.480 %	1,904,864	3.480 %	65 M $
BNY Mellon Investment Adviser, Inc. 3.221 %	1,762,898	3.221 %	60 M $

Supernus Pharmaceuticals, Inc.

9715 Key West Avenue

20850, Rockville

+301 838 2500

http://www.supernus.com

address Supernus Pharmaceuticals, Inc.(SUPN)

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29.99 USD

Average target price

40.33 USD

Spread / Average Target

+34.49%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SUPERNUS PHARMACEUTICALS, INC.	+4.37%	1.64B
MERCK KGAA	+4.86%	70.36B
KYOWA KIRIN CO. LTD.	+12.11%	9.26B
SK BIOPHARMACEUTICALS CO., LTD.	-16.73%	4.72B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+23.84%	3.89B
YUHAN CORPORATION	+1.45%	3.75B
INDIVIOR PLC	+29.79%	2.66B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-24.17%	2.37B
BETTA PHARMACEUTICALS CO., LTD.	-27.04%	2.17B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	-3.78%	1.75B

Specialty & Advanced Pharmaceuticals